Paula Rodríguez‐Otero

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study

Sagar Lonial, Hans C. Lee, Ashraf Badros et al. · The Lancet Oncology · 2019 · 796 citations

Medicine, Pharmacology, Pharmacotherapy +11

Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma

Paula Rodríguez‐Otero, Sikander Ailawadhi, Bertrand Arnulf et al. · New England Journal of Medicine · 2023 · 705 citations · Full text

Medicine, Immunology, Oncology +17

Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma

Ajai Chari, Monique C. Minnema, Jesús G. Berdeja et al. · New England Journal of Medicine · 2022 · 649 citations · Full text

Medicine, Immunology, Pharmacology +17

Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results

Alexander M. Lesokhin, Michael H. Tomasson, Bertrand Arnulf et al. · Nature Medicine · 2023 · 564 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

Pieter Sonneveld, Meletios Α. Dimopoulos, Mario Boccadoro et al. · New England Journal of Medicine · 2023 · 515 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17